Moreover, engineered oncolytic viruses specifically designed to kill cancer cells have shown a significant impact on GBM progression since these viral particles expressing IL-12 increased tumor cell death and shifted the TAMs towards a pro-inflammatory phenotype, improving anti-PD1 and anti-CTLA-4 immunotherapies outcomes (177) (Figure 3). This evidence concerns the gene CTLA4 and neoplasm.